AIM ImmunoTech said the final subject has received a first dose in the Phase 2 DURIPANC trial of Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 therapy. The update indicates continued clinical progress, but it is a routine trial-milestone announcement rather than data showing efficacy or safety results. Market impact should be limited unless later readouts are positive.
AIM ImmunoTech said the final subject has received a first dose in the Phase 2 DURIPANC trial of Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 therapy. The update indicates continued clinical progress, but it is a routine trial-milestone announcement rather than data showing efficacy or safety results. Market impact should be limited unless later readouts are positive.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
